Bill Summary
This resolution expresses support for making testing for antiphospholipid syndrome (APS) a standard component of prenatal screening. APS is an autoimmune disorder where the immune system produces antibodies that can lead to an increased risk of blood clots, which in turn can cause miscarriages, stillbirths, and other pregnancy complications. Currently, medical guidelines suggest testing for APS only in specific cases, such as after unexplained fetal losses. The resolution highlights that APS accounts for approximately 15 percent of recurrent pregnancy losses and emphasizes the importance of early detection through a simple blood test, which can be treated with blood thinners. By endorsing this testing as part of routine prenatal care, the resolution aims to save lives and alleviate the emotional burden on families experiencing pregnancy loss. It calls upon medical associations to revise their recommendations to include APS testing as standard practice.
Possible Impacts
The resolution advocating for the inclusion of antiphospholipid syndrome (APS) testing as a standard part of prenatal screening could have several significant effects on individuals and families. Here are three examples:
1. **Improved Pregnancy Outcomes**: By supporting the testing for APS as a standard part of prenatal screening, more women may receive an early diagnosis of the condition. This could lead to timely interventions, such as the administration of blood thinners, which could significantly reduce the risk of miscarriages, stillbirths, and other pregnancy complications associated with APS. Consequently, families might experience healthier pregnancies and increased chances of live births.
2. **Reduced Emotional and Psychological Burden**: Currently, women who suffer recurrent pregnancy losses or complications due to undiagnosed APS may experience significant emotional distress and grief. By making APS testing standard practice, many families could avoid repeated losses and the associated trauma. This proactive approach could result in better mental health outcomes for women and families, as they might experience less anxiety and despair surrounding pregnancy.
3. **Enhanced Awareness and Education**: As professional medical associations and guideline-setting bodies update their recommendations to incorporate APS testing, there could be a broader awareness of the condition among healthcare providers and patients. This increased knowledge may lead to better-informed discussions between healthcare providers and expectant mothers regarding potential risks in pregnancy. Improved education on APS could empower women to seek appropriate care and advocate for their health, ultimately fostering a more supportive healthcare environment.
[Congressional Bills 119th Congress]
[From the U.S. Government Publishing Office]
[H. Res. 685 Introduced in House (IH)]
<DOC>
119th CONGRESS
1st Session
H. RES. 685
Expressing support for testing for antiphospholipid syndrome (APS) as a
standard part of prenatal screening, and for other purposes.
_______________________________________________________________________
IN THE HOUSE OF REPRESENTATIVES
September 9, 2025
Mrs. Cammack (for herself, Ms. Kamlager-Dove, Mrs. Kim, Ms. Pettersen,
Mrs. Hinson, Ms. Adams, Mrs. Cherfilus-McCormick, and Mr. Landsman)
submitted the following resolution; which was referred to the Committee
on Energy and Commerce
_______________________________________________________________________
RESOLUTION
Expressing support for testing for antiphospholipid syndrome (APS) as a
standard part of prenatal screening, and for other purposes.
Whereas antiphospholipid syndrome (APS) is a condition in which the immune
system of an individual mistakenly produces antibodies that increase the
risk of blood clots;
Whereas APS can increase the risk of miscarriages, stillbirths, and pregnancy
complications;
Whereas professional medical associations and guideline-setting bodies do not
recommend testing for APS as a standard part of prenatal screening;
Whereas professional medical associations and guideline-setting bodies recommend
testing for APS only if a woman has an unexplained fetal loss after 10
weeks or 3 or more unexplained embryonic losses (miscarriages);
Whereas APS is responsible for about 15 percent of recurrent pregnancy losses;
Whereas the total number of miscarriages caused by APS is unknown because it is
not tested as part of normal prenatal screening;
Whereas APS can be detected by a blood test and treated by blood thinners; and
Whereas testing for APS during normal prenatal screening can save babies and
reduce grief for women and families: Now, therefore, be it
Resolved, That the House of Representatives--
(1) supports testing for antiphospholipid syndrome (APS) as
a standard part of prenatal screening; and
(2) calls upon professional medical associations and
guideline-setting bodies to update their recommendations to
include testing for APS as a standard part of prenatal
screening.
<all>